Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Avatrombopag.
- Who it may be relevant to
- Registry conditions: Immune Thrombocytopenia, Autoantibodies, Evan Syndrome, Connective Tissue Diseases. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Efficacy and Safety of Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Fail to Eltrombopag or Herombopag Treatment: a Single-center, Prospective, One-arm Clinical Trial
Overview
This prospective, open-label, single-center, one-arm clinical trial aims at evaluating the efficacy and safety of avatrombopag in Chinese adult Immune Thrombocytopenia (ITP) patients with autoantibodies fail (due to intolerance or resistance) to eltrombopag or herombopag treatment.
Detailed description
This prospective, open-label, single-center, one-arm clinical trial aims at evaluating the efficacy and safety of avatrombopag in Chinese adult ITP patients with autoantibodies fail (due to intolerance or resistance) to eltrombopag or herombopag treatment.
The subjects include ITP secondary to connective tissue diseases (including but not limited to systemic lupus erythematosus, Sjogren's syndrome and rheumatoid arthritis), primary ITP with positive antinuclear antibody but not up to the diagnostic criteria of connective tissue diseases, primary Evans syndrome, Evans syndrome secondary to connective tissue diseases, and primary ITP with positive Coomb's test but not up to the diagnostic criteria of Evans syndrome.
Fifty-two eligible subjects will be enrolled in this study. The dose will be adjusted according to the platelet count during the period from week 1 to week 12.
Interventions
- Drug Avatrombopag
The subjects will receive avatrombopag treatment with an initial dose of 40mg once a day. Platelet counts will be obtained weekly during the first 4 weeks and then every 2 weeks until week 12 after treatment. The dose adjustment range is 20 mg per week to 40 mg per day to maintain the platelet level between 30×10\^9/L and 200×10\^9/L. If the platelet count does not reach to 30×10\^9/L after taking avatrombopag 40mg once a day for 4 consecutive weeks, the treatment will be stopped.
Primary outcome measures
- Platelet response [Time frame: From the start of study treatment (Day 1) up to the end of week 12.]
Secondary outcome measures (12)
- Platelet response [Time frame: From the start of study treatment (Day 1) up to the end of week 12.]
- Platelet response [Time frame: From the start of study treatment (Day 1) up to the end of week 12.]
- Duration of platelet response [Time frame: From the start of study treatment (Day 1) up to the end of week 12.]
- Platelet response [Time frame: From the start of study treatment (Day 1) up to the end of week 12.]
- Time to platelet response [Time frame: From the start of study treatment (Day 1) up to the end of week 12.]
- Duration of platelet response [Time frame: From the start of study treatment (Day 1) up to the end of week 12.]
- Proportion of patients receiving remedial treatment. [Time frame: From the start of study treatment (Day 1) up to the end of week 12.]
- Bleeding score [Time frame: From the start of study treatment (Day 1) up to the end of week 12.]
- Changes of disease activity index in patients with systemic lupus erythematosus [Time frame: From the start of study treatment (Day 1) up to the end of week 12.]
- The improvement of symptoms [Time frame: From the start of study treatment (Day 1) up to the end of week 12.]
- Improvement in immune indexes [Time frame: From the start of study treatment (Day 1) up to the end of week 12.]
- Discontinuation rate of glucocorticoids [Time frame: From the start of study treatment (Day 1) up to the end of week 12.]
Eligibility criteria
Inclusion criteria
- The patients have provided written informed consent prior to enrollment.
- Men and women greater than or equal to 18 years of age.
- Diagnosed as ITP secondary to connective tissue diseases (including but not limited to systemic lupus erythematosus, Sjogren's syndrome and rheumatoid arthritis), primary ITP with positive antinuclear antibody but not up to the diagnostic criteria of connective tissue diseases, primary Evans syndrome, Evans syndrome secondary to connective tissue diseases, and primary ITP with positive Coomb's test but not up to the diagnostic criteria of Evans syndrome.
- Platelet count<30 ×10\^9/L at screening.
- Patients who have previously failed to receive Eltrombopag or Herombopag \[poor efficacy (Eltrombopag 75 mg/d or Herombopag 7.5 mg/D, at least 4 weeks), or the efficacy cannot be maintained\], or who have contraindications, can not tolerate or refuse Eltrombopag or Herombopag treatment.
- Treatment for ITP (including but not limited to glucocorticoids, recombinant human thrombopoietin, and other thrombopoietin receptor agonists other than Avatrombopag) must be completed before enrollment, or the dose must be stable or in a phase of reduction within 2 weeks before enrollment.
- Effective contraceptive measures will be taken during the clinical trial.
Exclusion criteria
- Patients with active thyroid disease requiring treatment.
- Patients with any prior history of arterial or venous thrombosis within 3 months, and with any of the following risk factors: cancer, Factor V Leiden, ATIII deficiency, or patients who are using anticoagulants or antiplatelet drugs at the beginning of screening.
- Those who had received rituximab within 3 months.
- Patients who had failed to respond to the previous use of Avatrombopag (40mg once a day for more than 4 weeks).
- Subjects known to be allergic to Avatrombopag or any of its excipients.
- Patients who had received splenectomy within 3 months or have splenectomy plan within 3 months.
- Patients with lupus encephalopathy or lupus nephritis.
- Patients with cataract.
- Patients with infectious fever (including but not limited to pulmonary infection) within 1 month or with active infection during screening.
- Existing hepatitis B virus, hepatitis C virus replication or HIV infection.
- Severe liver dysfunction (alanine aminotransferase or glutamic oxaloacetic transaminase > 3×ULN).
- Patients with severe cardiac or pulmonary dysfunction.
- Severe renal damage (creatinine clearance < 30 ml/min).
- There are surgical planners during the study.
- History of psychiatric disorder.
- Pregnant or lactating women or those planning to be pregnant during the trial.
- Patients with a history of drug/alcohol abuse (within 2 years before the study).
- Patients that had participated in other experimental researches within one month before enrollment.
- Any other circumstances that the investigator considers that the patient is not suitable to participate in the trial.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 1 center
- Institute of Hematology & Blood Diseases Hospital — Tianjin
Identifiers
NCT: NCT04993885 · IIT2021033